Table 1.

Clinical characteristics of RMD participants who withheld peri-vaccination mycophenolate

Participant	Age	Sex	Race	Diagnosis	Vaccine type	Mycophenolate Dose	Number of doses held	Concurrent Therapy	Antibody Titer *	Flare
1	36	M	White	CT-ILD†	Moderna	2000mg	3	No	>250	No
2	62	F	White	CT-ILD†	Pfizer	500mg	88	Prednisone	>250	No
3	19	F	White	IA‡	Pfizer	1000mg	5	Abatacept	16	Yes
4	58	F	White	IA‡	Pfizer	2000mg	28	Tofacitinib	>250	No
5	46	F	White	Myositis	J+J	2000mg	NA	Prednisone	82	No
6	53	F	White	Myositis	J+J	2500mg	56	Prednisone	206	No
7	46	F	White	Myositis	Pfizer	3000mg	20	IVIG§, HCQ||	40	No
8	54	F	White	Myositis	Pfizer	3000mg	NA	No	<0.40	No
9	35	F	White	Myositis	Moderna	3000mg	24	No	>250	No
10	71	F	White	Overlap CTD¶	Moderna	2000mg	4	Rituximab	9.0	No
11	58	F	White	Overlap CTD¶	Moderna	2000mg	9	HCQ||, Prednisone	8	No
12	55	F	White	Overlap CTD¶	Moderna	2000mg	30	HCQ||, Prednisone	8	No
13	64	F	White	Overlap CTD¶	Pfizer	500mg	38	No	>250	No
14	70	M	White	Scleroderma	Moderna	3000mg	42	Rituximab	<0.40	Yes
15	36	F	White	Scleroderma	Pfizer	3000mg	14	No	35	No
16	40	F	White	Scleroderma	Pfizer	2500mg	28	No	244	No
17	42	F	White	Scleroderma	Pfizer	3000mg	8	Abatacept	22	No
18	63	F	White	Sjogren’s	Pfizer	2500mg	NA	No	12	No
19	49	F	White	SLE	J+J	3000mg	13	No	>250	No
20	54	F	White	SLE	Moderna	1000mg	10	HCQ‡	>250	No
21	50	F	Black	SLE	Pfizer	3000mg	98	Belimumab, Prednisone	>250	No
22	31	F	White	SLE	Pfizer	2000mg	10	HCQ‡, Prednisone	80	No
23	38	F	White	SLE	Pfizer	1500mg	20	Prednisone	168	No
24	51	F	White	SLE	Moderna	1000mg	5	Abatacept	>250	No

^*The assay ranges from <0.4 to >250 units/mL. Positive antibody was defined as an anti-SARS-CoV-2 RBD antibody titer >0.79 units/mL

^†Denotes connective tissue disease related ILD

^‡Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, or inflammatory bowel disease associated arthritis

^§Intravenous Immunoglobulin

^||Hydroxychloroquine

^¶Denotes a combination of two or more of the rheumatic conditions